Friday, January 27, 2012

Site Search

Archive for June, 2011

Ovarian Cancer Analysis Points to Common Gene Mutation, Research Says

Genetic mutations frequently found in the most common form of ovarian cancer were catalogued by U.S. scientists, paving the way for a more effective treatment of the disease.

The detailed genetic map already helped scientists identify existing drugs with the potential for treating the mutations found in ovarian cancer tumors and also identified mutations that could respond to new drugs.

The study, published Wednesday in the journal Nature, will contribute to a more personalized approach to cancer medicine because doctors will be able to treat patients according to the genetic mutations that drive the growth and spread of their tumors.

Scientists hope that the Cancer Genome Atlas project findings will allow them to understand how some genes cause cancer and develop drugs that control them.

Francis Collins — the director of the U.S. National Institutes of Health, in Bethesda, Md., which funded the research — said that “this landmark study is producing impressive insights into the biology of this type of cancer. It will significantly empower the cancer research community to make additional discoveries that will help us treat women with this deadly disease.”

In the study, scientists analyzed 316 ovarian tumors and found that the gene TP53 was present in 96 percent of the cancers. The study also found 108 genes linked to poor survival and 85 genes associated with better survival.

Ovarian Cancer is the fourth most common cause of female cancer deaths in the U.S. and kills nearly 14,000 women in the country each year.

Source: http://www.foxnews.com/health/2011/06/30/ovarian-cancer-analysis-points-to-common-gene-mutation-research-says/

The Second Disease To Ever Be Globally Eradicated: Rinderpest

One of the greatest scourges of human history is no more. For only the second time, modern public health practices have managed to eradicate a pandemic illness of global reach. The first was smallpox. Now what? AIDS? TB? No. Today, the world’s cattle are safe from rinderpest.

If you’ve never heard of rinderpest, it’s likely because you live in America, where thanks to the quarantine of distance and history the disease never established itself. But in the old world, cattle have kept company with humans for some 8,000 years, often in settings of extraordinary intimacy. Farm families throughout Europe lived in crofts, homes that doubled as stables; pastorlists like the Nuer people of Sudan, who drink not only cows’ milk but their blood as well, rely on cattle to supply nearly all their needs.

Through the many generations of coexistence, humans and their domesticated herds have shared their illnesses; smallpox, the only other disease eradicated by modern public health practices, likely began among cattle (the first smallpox vaccines were made by scraping matter from lesions on cows). In rinderpest, we humans returned the favor–scientists now think that the disease, a relative of measles, evolved from the human pathogen as recently as a thousand years ago.

Although no human ever fell ill from rinderpest, its toll on our species has been considerable. With mortality rates among afflicted herds approaching 90 percent, rinderpest outbreaks quickly starved populations of cattle-dependent farmers. In East Africa, its introduction had much the same effect as human diseases did in the New World in the wake of first European contact, laying waste to entire societies and rendering them defenseless in the face of colonialism. It has been blamed for the stagnation of agricultural economies and the rise and fall of empires. Though the last case was seen in 2001, farmers can now rest easy knowing the disease is fully contained. The benefits of rinderpest-free herds to agrarian economies will only grow with time.

Rinderpest’s eradication depended on recent innovations in medical practice. It took a combination of technical advances, including a new form of vaccine that doesn’t need to be refrigerated; and culturally-sensitive public health protocols, relying on local veterinary assistants rather than pith-helmeted foreign specialists to manage the disease in its far-flung pastures. Its eradication is evidence of one of the curious insights of modern public health: that while disease is global, medicine often takes a village.

Source: http://www.fastcompany.com/1764227/the-eradication-of-rinderpest

Coffee buzz protects brain from Alzheimer’s

For years we’ve been told that caffeinated coffee was bad for us. It’s unhealthy and addictive, doctors warned. But as vindication for all who stuck by their energizing elixir, a new study shows that guzzling caffeinated coffee may actually be good for our brains. In fact, it may help keep Alzheimer’s at bay.

The study, which was published early online in the Journal of Alzheimer’s Disease, was in mice whose DNA had been tweaked to contain a human Alzheimer’s gene. Just like humans with familial Alzheimer’s, these mice become increasingly forgetful as they age.

Amazingly, the equivalent of four to five cups of caffeinated coffee every few days led to much improved memories in the Alzheimer’s mice, says study co-author Gary Arendash, a scientist at the Florida Alzheimer’s Disease Research Center in Tampa.

Earlier research by Arendash and his colleagues showed that caffeine could at least partially block the production of beta amyloid, the sticky protein that clogs the brains of Alzheimer’s patients. They also found that a substance called granulocyte-colony stimulating factor, or GCSF, sparked the production of new axons, the communication cables that link nerve cells together, as well as new nerve cells themselves.

What’s really interesting is that caffeinated coffee — but not decaf — boosted the production of GCSF.

For the new study, Arendash and his colleagues “treated” healthy mice and Alzheimer’s mice with either caffeinated or decaffeinated coffee. Then the researchers ran a test to see if either beverage led to better memories.

The test they used mimics one that is given to humans to diagnose Alzheimer’s. In that test, people are given a bag of objects to look through (we’ll call that Bag A). And then they’re shown another bag of objects (Bag B). Later on, they’re asked to remember what was in Bag A.

Studies have shown that people with Alzheimer’s have a tough time remembering what was in Bag A because the distraction of looking through the objects from Bag B gets in the way of storing the contents of A in their long term memories. That’s generally not a problem for people with healthy brains.

The two part mouse test involved water mazes. The mice has to find — and remember — the location of a submerged platform in a tub of water that is deep enough that they need to swim till they find the platform.

After they find the platform in one tub, they’re moved to another tub where they have to find yet another platform. Mice with Alzheimer’s generally have a tough time remembering the location of the first platform when they’re placed in the original tub. But in Arendash’s study, Alzheimer’s mice that got caffeinated coffee had memories that were just as good as those of normal mice.

Lest you dismiss this study because it’s just in rodents, Arendash says he’s got new data in humans. That data is still being analyzed, he says, but so far it looks like caffeinated coffee has the same impact in people as it does in mice.

Source: http://bodyodd.msnbc.msn.com/_news/2011/06/28/6968218-coffee-buzz-protects-brain-from-alzheimers

Hemophilia Is Target of Therapy on Genome

Researchers using a new technique for editing the genome of living cells have shown that they can cure hemophilia in mice, at least in principle, with a couple of injections that carry out the “cut” and “paste” operations needed to insert a corrective gene.

This is the first time this genome-editing technique has succeeded in a live animal. Along with other applications, like two AIDS treatments in preliminary stages, the new technique could be the decisive improvement that gives credibility to the long-struggling field of gene therapy.

“This may well revolutionize the field, but it won’t do so overnight,” said Dr. Katherine A. High of the Children’s Hospital of Philadelphia, the research team leader. “Any novel kind of therapeutic takes time to develop.”

The essence of the technique is the molecular scissors custom-designed to cut the genome at a unique site. This allows the corrective gene to be inserted at the right place in a chromosome.

In previous forms of gene therapy, corrective genes have been inserted into the genome at random sites, for lack of the ability to control where they go. This approach means they are not under their natural control systems and, worse, may be inserted in the middle of some other gene that they disrupt.

“There’s a huge interest in this,” said Dr. Mark A. Kay, a gene therapist at the Stanford University School of Medicine. The genome editing approach “could be game-changing in some applications,” he said.

The technique depends on natural agents called zinc finger proteins whose role is to bind to specific sites on the genome and control adjacent genes. By mixing and matching the DNA of different natural zinc finger proteins, researchers can create artificial zinc fingers for any chosen target site on the genome.

In their genome-editing role, the zinc fingers are attached to a DNA-cutting enzyme derived from a bacterium. When a pair of zinc finger proteins line up on opposing strands of DNA, their DNA cutters face each other and scissor the DNA apart.

The zinc finger technique has been developed by Sangamo BioSciences and by academic researchers who belong to the Zinc Finger Consortium. “We are fairly inundated with requests,” said Philip D. Gregory, Sangamo’s chief scientific officer.

Sangamo designed the zinc finger pairs for Dr. High’s hemophilia project. But the fingers are designed to cut the human Factor 9 gene, not the mouse version, which has a different sequence of DNA units. So Dr. High genetically engineered a strain of hemophiliac mice that carry a mutated version of the human Factor 9 gene in place of their own.

After the cut-and-paste operation, the mice possessed a good working copy of human Factor 9, producing enough to make their blood clot much faster, and well enough to prevent hemophilia, Dr. High and her colleagues report in the journal Nature. To show that the new gene was stably incorporated into cells, they then cut out part of the mice’s livers. The liver regenerated from existing cells, retaining their ability to produce good copies of Factor 9.

Dr. High said it was too soon to try the technique in people, given that an adequate treatment for hemophilia already exists. She plans to test it next in dogs, which are a standard model for new hemophilia treatments. One of the possible problems with the technique is that the zinc fingers sometimes cut at sites other than the intended target site.

Dr. High said that besides hemophilia, the zinc finger technique could address many other liver-based genetic diseases.

Zinc fingers are being used in a different way in a treatment for AIDS, at present in early clinical trials. The fingers are used to disrupt a gene called CCR5, which makes the receptor used by the AIDS virus to gain access to cells. People with no CCR5 receptor are naturally immune to AIDS.

The hope is that patients will acquire the same immunity after their T cells are treated with zinc fingers and returned to the body.

“We are very hopeful that zinc finger technologies will have a spectacular impact on gene therapy and genetic medicine in general,” Dr. Gregory said.

Source: http://www.nytimes.com/2011/06/27/us/27therapy.html

Genentech to Appeal to F.D.A. for Breast Cancer Drug

Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works.

At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its proposal last December to revoke the approval of Avastin for breast cancer on the grounds that new studies did not confirm that the drug helped patients.

Genentech’s approach seems intended to broaden the terms under which Avastin can remain available. The company is arguing that even if the F.D.A. reaffirms that data do not support Avastin’s effectiveness, the approval should be retained while Genentech does one more clinical trial. Avastin has remained available for breast cancer pending the appeal process.

Avastin was put on the market under an accelerated program begun in the early 1990s that allows drugs for serious diseases to be approved with less than the usual amount of evidence, subject to further studies. Dozens of drugs have been approved this way, and in at least a couple of cases approvals have been withdrawn. But this is the first time the F.D.A. will hold a hearing to consider a company’s appeal.

The debate over Avastin has evoked passions on both sides among those involved in women’s health issues. Some patient advocates argue that the F.D.A. needs to revoke the approval to maintain the integrity of the accelerated process and to ensure that cancer patients receive drugs that work.

But some breast cancer patients are expected to testify at the hearing that the drug should be kept available because it helps some women, even if not all.

“It’s so depressing to think that a federal agency can make a decision that can potentially cause me to die,” said Crystal Hanna, 35, a mother of two from Parkersburg, W.Va., who said Avastin has kept her cancer under control for almost a year.

The public comments sent to the F.D.A. before the hearing at its campus outside Washington, overwhelmingly support retaining the approval. Many of them, using virtually identical language, cite the case of Ms. Hanna, who drafted a comment for friends that circulated widely on the Internet.

Even if approval as a breast cancer treatment is ultimately rescinded, Avastin will retain approval to treat lung, colon, kidney and brain cancers. So doctors will be able to use it “off label” to treat breast cancer. But insurers might no longer pay for it for that use, putting the drug, which can cost $88,000 a year, out of reach for many women.

The Avastin issue has become caught up in the politics of overhauling health care, with some critics saying the decision not to pay for it represents rationing and others saying that Medicare should not pay for a drug that does not work. The F.D.A. maintains that it is not permitted to consider costs.

The ultimate decision will be made by the F.D.A. commissioner, Dr. Margaret A. Hamburg, who appears to have some latitude. The rules say that the F.D.A. “may” revoke the approval of a drug, but does not have to.

“Even where F.D.A. determines that confirmatory trials do not establish clinical benefit, withdrawal is not required and instead should be based on the public health considerations that motivate the accelerated approval statute,” Genentech argues in a summary of its arguments filed before the hearing.

But the F.D.A.’s drug division views the company’s request as a stalling tactic. “How many bites of the apple do you get?” Dr. Richard Pazdur, the director of the agency’s oncology drug division, said in an interview at a cancer conference early this month.

The agency, in a summary of its arguments, says that because it has already determined that the benefits of Avastin do not outweigh the risks, retaining the approval while the new study is conducted “would not be in the interest of the public health and would jeopardize the integrity of the accelerated approval program.”

Genentech and its parent company, Roche, could lose as much as $1 billion in annual sales if the breast cancer approval were revoked. Already Avastin sales for treatment of breast cancer have started declining. The drug is the world’s best-selling cancer drug, with sales last year of roughly $7 billion.

The F.D.A. approved the drug for advanced breast cancer in February 2008, after one clinical trial showed that combining Avastin with another drug, paclitaxel, delayed the median time before tumors worsened by 5.5 months, compared with using paclitaxel alone. But the women who got Avastin did not live significantly longer than those who got only paclitaxel, which is also known by the brand name Taxol.

Subsequent trials, in which Avastin was combined with different chemotherapy drugs, showed a much smaller delay in tumor progression, ranging from less than 1 month to 2.9 months. And again there was no improvement in survival for those receiving Avastin.

Based on those results and on the fact that Avastin has some life-threatening side effects, including bowel perforation and hemorrhaging, the F.D.A.’s cancer drug advisory committee voted 12 to 1 last July that the approval for the treatment of breast cancer be revoked.

The hearing this week will be before the same committee, which will make recommendations to the F.D.A. commissioner. Of the six voting committee members expected to attend, five voted to revoke the approval last July. The sixth was not at that earlier meeting. Since the data have not changed, Genentech, in the summary of its arguments, concedes it is not likely to change the committee’s mind about the benefits of Avastin.

Instead it will argue that the drug with which Avastin is combined matters. Therefore, the company should be given a chance to do another trial in which Avastin is combined with paclitaxel, as in the original trial that led to the drug’s approval.

Source: http://www.nytimes.com/2011/06/27/health/27drug.html

Experimental Type 1 diabetes vaccine fails during second step of trial

The quest for a vaccine to stop Type 1 diabetes in its tracks has hit a roadblock.

An experimental drug failed in the second step of a three-phase trial on 145 American and Canadian patients who had just been diagnosed with the disease.

The vaccine is based on an enzyme that is targeted by a diabetes patient’s immune system.

Researchers hoped the vaccine would train the immune system to not attack the enzyme – a process that destroys the pancreas’ insulin-producing cells.

But according to a study published by the medical journal The Lancet on Monday, patients who got the vaccine experienced no difference in the progression of the disease.

The vaccine was aimed at Type 1 diabetes, which used to be known as juvenile diabetes and affects less than 10% of people with the disease.

Most sufferers have what’s known as adult-onset or Type 2 diabetes.

New research shows vitamin D may ward off those at risk for Type 2 from actually developing the disease.

A study released over the weekend revealed that patients with the high levels of the vitamin were 25% less likely than those with the lowest amounts to get diabetes.

Scientists theorize that vitamin D may help the body produce more insulin or increase the body’s sensitivity to insulin.

Source: http://www.nydailynews.com/lifestyle/health/2011/06/27/2011-06-27_experimental_type_1_diabetes_vaccine_fails_during_second_step_of_trial.html?r=news/national

Kidney improvement sustained by Abbott drug-study

NEW YORK, June 24 (Reuters) – Diabetics with moderate to severe chronic kidney disease showed significant and sustained improvement in kidney function through 52 weeks of treatment with a novel drug being developed by Abbott Laboratories (ABT.N), according to data from a midstage clinical trial.

The oral drug, bardoxolone methyl, is the first medicine to demonstrate improvement in kidney function in patients with the deadly disease and could delay the need for expensive and inconvenient kidney dialysis, researchers said.

Current treatments, which are primarily blood pressure control medicines, have only been able to slow progression of chronic kidney disease.

“This is totally unique in my 20-plus years of treating patients with chronic kidney disease. There’s nothing out there that increases kidney function,” Dr. David Warnock, who presented the data at a European kidney meeting in Prague on Friday, said in a telephone interview.

“The important improvement we saw at the primary endpoint of week 24 is persisting and sustained throughout the entire 52 weeks of treatment,” Warnock added.

Bardoxolone showed statistically significant kidney improvement compared with placebo at all three doses tested — 150 milligrams, 75mg and 25mg — researchers said.

Based on the results of the 227-patient study, Abbott and its partner, privately-held Reata Pharmaceuticals, which discovered the drug, selected the 75mg dose for a recently initiated pivotal Phase III trial.

Bardoxolone is the first drug from a new class called antioxidant inflammatory modulators that work by suppressing inflammation, researchers said.

Patients in the midstage trial had Type 2 diabetes and moderate to severe chronic kidney disease, defined by an estimated glomerular filtration rate (eGFR) of 20 to 45. A person with normally functioning kidneys has an eGFR — a common measure of kidney function — of 100.

The Abbott drug raised eGFR by nearly 30 percent compared with placebo at the two higher doses. Those who got the 75 mg dose had an average eGFR improvement of 10.5, while 150mg patients saw a 9.5 eGFR improvement.

About 21 percent of placebo patients suffered a significant loss of kidney function (more than 25 percent) over the course of the 52 weeks, which is typical for the progressive disease, researchers said.

That compared with just 9 percent with significant kidney function loss for bardoxolone patients, meaning 91 percent experienced beneficial effects on kidney function, Warnock explained.

“What we have now today is a very promising data set that would suggest there is a possibility we can actually improve kidney function even in patients who have far advanced severe chronic kidney disease,” said Warnock, a professor of medicine in the division of nephrology at the University of Alabama in Birmingham.

“If this is confirmed as being clinically significant in terms of benefit to these patients, the prospects are very, very exciting,” he added.

The 1,600-subject Phase III trial will determine whether the new drug can delay progression to dialysis or cardiovascular death among very high risk kidney patients with diabetes.

The most common adverse side effect seen with bardoxolone methyl included muscle spasm, transient elevations in liver enzymes and nausea.

Most of the side effects seen in the first 24 weeks of treatment had moderated or subsided during the latter portion of the study, Warnock said.

“The adverse effect profile was something that we’re quite comfortable with, and we feel comfortable moving forward now with the definitive Phase III outcomes study,” he said.

An estimated 20 million Americans have chronic kidney disease; about 500,000 are on dialysis or in need of transplants, according to the National Kidney Foundation.

Diabetes is the most common cause of end stage renal disease, which progresses to a need for kidney dialysis and death.

“To keep patients off the dialysis machine will be a huge impact in terms of quality of life,” Warnock said.

In addition, end stage renal disease patients consume a huge portion of the Medicare budget compared to their numbers, he said.

“If we can keep people off dialysis, which costs about $75,000 a year, that would be just absolutely huge,” he said.

Results of the Phase II study presented in Prague are also being published in the New England Journal of Medicine. (Reporting by Bill Berkrot; editing by John Wallace)

Source: http://www.reuters.com/article/2011/06/24/abbott-kidney-idUSN1E75L0XM20110624

Pfizer’s Remoxy Fails to Win FDA Approval

WASHINGTON — The latest attempt at an abuse-resistant formulation of oxycodone (Remoxy) failed to win approval from the FDA, according to a statement from Pfizer.

Late Thursday, the company said it had received a complete response letter from the FDA, which described the reasons for the FDA’s decision.

The FDA had turned down an earlier version of the drug in 2008, but Pfizer’s King Pharmaceuticals re-submitted the new drug application in January.

Olivier Brandicourt, Pfizer president and general manager, said in the statement that the company was “working to understand and address the issues in the FDA Complete Response Letter. Pain is an important strategic disease area for Pfizer. We share the concern about misuse and abuse of opioid medicines and are committed to being part of the solution to address this important public health and safety issue.”

Pfizer was, however, successful with another abuse-resistant product — its short-acting oxycodone product, Oxecta, which was approved earlier in the week. An earlier formulation of that drug, too, had been turned down by an FDA advisory panel, but was okayed after the company removed the niacin from its recipe, which was meant to deter oral abuse.

The Oxecta only deters crushing, chewing, snorting, and injecting — not pill-popping.

Making drugs harder to abuse has been one key strategy for some companies in an attempt to control what the government has deemed an epidemic of prescription painkiller abuse.

Source: http://www.medpagetoday.com/PainManagement/PainManagement/27252

New Drug Effectively Treats Hepatitis C

WEDNESDAY, June 22 (HealthDay News) — The recently approved drug Incivek, combined with two standard drugs, is highly effective at treating hepatitis C, a notoriously difficult-to-manage liver disease, two new studies show.

Click here to find out more!

The drug works not only in patients just starting treatment, but in those who failed earlier treatment, the research found.

The hepatitis C virus can lurk in the body for years, causing liver damage, cirrhosis and even liver failure.

“This is a significant advance in the treatment of hepatitis C,” said Dr. David Bernstein, chief of the division of gastroenterology, hepatology and nutrition at North Shore University Hospital in Manhasset, N.Y., who was not involved in either study.

“We know that if we can get rid of the hepatitis C, we can prevent the progression of [liver] disease,” he said. “This means we can prevent the progression of cirrhosis, we can prevent the development of cancer and also prevent the need for liver transplantation in a large number of people.”

Incivek (telaprevir) was approved by the U.S. Food and Drug Administration in May and is the second drug in a class of drugs called protease inhibitors to be approved to fight hepatitis C. The other drug, called Victrelis (boceprevir), was also approved in May.

The standard treatment for hepatitis C has been a combination of two drugs, pegylated-interferon and ribavirin, which are given for a year. If protease inhibitors such as Incivek are added to the mix, the “viral cure” rate improves and the treatment time is reduced to six months, researchers found.

Both reports were published in the June 23 online edition of the New England Journal of Medicine.

In one study, a Phase 3 trial known as ADVANCE, patients were randomly assigned to either a placebo or the treatment in a double-blind study, which means that neither the patients nor the researchers know who’s getting the drug and who’s getting a sham treatment. This type of study is considered the gold standard for clinical research.

In the ADVANCE trial, 1,088 patients with hepatitis C who had never been treated for the condition were randomly assigned to standard therapy for 48 weeks, or telaprevir combined with standard therapy for eight or for 12 weeks, followed by standard therapy alone for a total treatment time of either 24 or 48 weeks.

The researchers found that 79 percent of those receiving Incivek for the longest period (24 weeks) had a “sustained response,” which basically means their hepatitis C was contained. Among those receiving standard care, 44 percent had a sustained response, the researchers noted.

“We have entered a new era of therapy for hepatitis C, which enables us to cure many more patients than we could before,” said lead researcher Dr. Ira M. Jacobson, from Weill Cornell Medical College in New York City.

Incivek needs to be given along with pegylated-interferon and ribavirin, Jacobson said. The researchers learned early on that Incivek alone reduces the level of the virus, but later the virus can become resistant to the drug, he said.

For the second study, called the REALIZE trial, 663 patients with hepatitis C who had failed standard therapy were divided into three groups. One group received Incivek plus standard therapy, another group was started on pegylated-interferon and ribavirin and then had Incivek added. The third group received standard therapy alone.

Here, the researchers found up to an 88 percent sustained response in patients receiving Incivek, compared with a 24 percent sustained response in the standard treatment group.

“These drugs represent a real milestone in the treatment of this disease,” said lead researcher Dr. Stefan Zeuzem, a professor of medicine at J.W. Goethe University Hospital in Frankfurt, Germany.

“There were very limited treatment options in the past, but now many patients have excellent chances to be cured, even if they already have advanced disease,” he said.

Bernstein noted that in the past, these patients could only be treated with more of the standard therapy for a longer period and the “cure” rate was only 10 percent. “Now you can treat these patients for six months with cure rates approaching 90 percent,” he said. “You are really offering hope to a large number of patients.”

The side effects of the medications include skin rashes, anemia, fatigue, itching, nausea, diarrhea, vomiting and taste changes. Some side effects were serious enough to cause a few participants to drop out, according to the study.

Incivek, made by Vertex Pharmaceuticals Inc., is sold to wholesalers for $49,200 for a four-week course of treatment, said Vertex spokeswomen Nikki Levy.

While both Incivek and Victrelis are important breakthroughs in the treatment of hepatitis C, new drugs with even fewer side effects and perhaps shorter treatment times are in clinical trials, Bernstein said.

Hepatitis C affects almost 4 million Americans, most of whom don’t know they’re infected. Often there are no symptoms, but it is the leading cause of liver transplantation in the United States and is linked to as many as 12,000 deaths a year, the researchers say.

Source: http://health.usnews.com/health-news/family-health/digestive-disorders/articles/2011/06/23/new-drug-effectively-treats-hepatitis-c?PageNr=1

Protein ‘helps predict Alzheimer’s risk’

A protein in spinal fluid could be used to predict the risk of developing Alzheimer’s disease, according to German researchers.

Patients with high levels of the chemical – soluble amyloid precursor protein beta – were more likely to develop the disease, they found.

Doctors said in the journal Neurology this was more precise than other tests.

Alzheimer’s Research UK said early diagnosis was a key goal, and the study represented a potential new lead.

Doctors analysed samples of spinal fluid from 58 patients with mild cognitive impairment, a memory-loss condition which can lead to Alzheimer’s.

The patients were followed for three years. Around a third developed Alzheimer’s.

Those who developed the illness had, on average, 1,200 nanograms/ml of the protein in the spinal fluid at the start of the study.

Those who did not started with just 932 nanograms/ml.

Beta amyloid proteins have already been implicated in Alzheimer’s itself, but not as a “predictor” of the disease.

The researchers said that a combination of soluble amyloid precursor protein beta, defective tau proteins, which are involved in the structure of brain cells, and a patient’s age was 80% accurate in predicting the onset of the disease.

Early diagnosis crucial

There is no cure for Alzheimer’s disease. If a treatment is developed, it is thought that it would need to be delivered early, before any permanent damage was done.

Dr Robert Perneczky, from the Technical University Munich, said: “Being able to identify who will develop Alzheimer’s disease very early in the process will be crucial in the future.

“Once we have treatments that could prevent Alzheimer’s disease, we could begin to treat very early and hopefully prevent the loss of memory and thinking skills that occurs with this devastating disease.”

More than 800,000 people have dementia in the UK, and that figure is expected to rise as populations get older.

Rebecca Wood, chief executive of Alzheimer’s Research UK, said: “The ability to diagnose Alzheimer’s early is a key goal for doctors and researchers. This small study provides a potential new lead to follow up.

“We will need to see larger trials before we can know how accurate this method could be as a diagnostic test. It will also be important to see how measurements of these proteins compare to those found in healthy people.”

Source: http://www.bbc.co.uk/news/health-13875984

Pfizer, Acura Say FDA Clears Painkiller Oxecta

Pfizer Inc. and Acura Pharmaceuticals Inc. said Monday the Food and Drug Administration approved a powerful painkiller that is designed to be harder to abuse.

The FDA cleared marketing of Oxecta as an immediate-release treatment for moderate to severe pain. The drug is designed to discourage common methods of abuse like crushing or dissolving, and it contains a compound that irritates the nose if it is snorted.

Shares of Acura, based in Palatine, Ill., rose 78 cents, or 20.2 percent, to $4.65 in afternoon trading. Earlier in the day its shares surged as much as 75.7 percent. Pfizer stock was unchanged at $20.26.

Oxecta is similar to Purdue Pharma LP’s OxyContin, the top-selling painkiller in the U.S. Regulators and health officials have pushed hard to get alternatives on the market after reports showed millions of people were abusing OxyContin and other prescription painkillers.

Acura and King Pharmaceuticals developed Oxecta under the name Acurox. Pfizer of New York bought King for $3.6 billion, and Oxecta is the first of King’s drugs to be approved since the deal closed in March. A second approval could come Thursday, as Pfizer is waiting for the FDA to return a decision on the drug candidate Remoxy.

OxyContin is an extended-release painkiller, however, and Citi Investment Research analyst John Boris said those drugs represent a larger market. Boris said annual sales of Oxecta could rise as high as $100 million, but Remoxy sales could reach $500 million a year.

Unlike those drugs, Oxecta is designed to start working right away.

Boris said he does not believe Remoxy will be approved this week, as Pfizer has disclosed a manufacturing issue that could delay approval. Remoxy was developed by Durect Corp. and licensed by Pain Therapeutics Inc. Pfizer now holds a sublicense from Pain Therapeutics.

Source: http://abcnews.go.com/Business/wireStory?id=13883837

UPDATE 1-Pfizer stop-smoking pill raises heart risk-FDA

WASHINGTON, June 16 (Reuters) – Pfizer Inc’s (PFE.N) stop-smoking drug Chantix can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday.

The Food and Drug Administration is changing the label for Chantix after reviewing the results of a clinical trial.

An independent randomized trial of 700 smokers with cardiovascular disease who were treated with Chantix or a placebo showed that Chantix was effective in helping paients quit smoking for as long as one year.

However, patients who took the pill were also slightly more likely to have a heart attack or other adverse cardiovascular event versus patients on a placebo.

Many smokers who try to quit do so to prevent the risk of heart attacks, which may now be associated with Chantix.

“The known benefits of Chantix should be weighed against its potential risks when deciding to use the drug in smokers with cardiovascular disease,” the FDA said in a statement.

The FDA said it is also requiring Pfizer to evaluate the cardiovascular safety of Chantix by conducting a large, combined analysis of randomized, placebo-controlled trials.

Pfizer’s non-nicotine pill has already come under fire for psychiatric side effects, which have crimped global sales and prompted the FDA to issue a restrictive “black box” warning label for the drug.

Investors had high hopes for the drug — called Champix in Europe — when Pfizer first launched its smoking-cessation aid in 2006, but reports of serious side effects have prevented strong sales growth.

Annual sales are now about $800 million, making the pill a moderate-sized product for the world’s biggest drug maker.

Chantix has been associated with agitation, depression and suicidal thoughts, and, in clinical trials, linked with nightmares. Psychiatric symptoms have occurred in people without a history of mental illness and have worsened in people who already had mental illness.

Source: http://www.reuters.com/article/2011/06/16/drugs-fda-chantix-idUSN1618502520110616

Genome Maps Solve Medical Mystery For Calif. Twins

Ever since scientists began to sequence the entire genomes of individuals —beginning with those of Nobelist James Watson and scientific entrepreneur J. Craig Venter in 2007 — skeptics have wondered just how useful this elegant and expensive trick would become.

A pair of 14-year-old twins, Alexis and Noah Beery, now provide a compelling answer, even if it’s not yet clear how generalizable their case is to others with genetic disorders.

Whole-genome sequencing has enabled doctors to provide the Beery twins with a simple, highly effective treatment for a rare condition called DRD, or dopa-responsive dystonia. The tale of their cure appears in this week’s issue of the journal Science Translational Medicine.

The twins were diagnosed with cerebral palsy at age two. But their mother, Retta Beery, didn’t think that was correct. For one thing, Alexis’s contorted posture and jerky movements always seemed to be better in the morning and increased as the day went on.

Turns out DRD is known for these diurnal variations, as Retta found out through dogged research. That led to a diagnosis of DRD when the twins were five. Since DRD was thought to be a deficiency of the neurotransmitter dopamine, low doses of a drug called L-dopa (also used for Parkinson’s disease) rather miraculously made the twins’ “cerebral palsy” go away within days.

But other symptoms persisted and worsened. At age 14, Noah had hand tremors, awkwardness and attentional problems. More alarmingly, Alexis had breathing problems due to spasms in her larynx. But when doctors probed for an explanation of these symptoms, the twins tested negative for known mutations of two genes known to be involved in DRD.

As it happens, the twins’ father, Joe Beery, works for a California biotech company that makes DNA sequencing machines. So the parents wondered if a deep dive into their twins’ DNA might explain the nature of their particular genetic defect.

Scientists at Baylor College of Medicine, a pioneer in whole-genome sequencing of individuals, thought it was worth a go. They sequenced the genomes of the twins, their older brother, their parents and their grandparents.

Comparing the results, the researchers found that the twins both inherited a gene variant from each parent that, together, led them to have low levels of not just dopamine but two other neurotransmitters, serotonin and noradrenalin.

The twins’ neurologist, Jennifer Friedman of Rady Children’s Hospital in San Diego, suggested giving the teenagers a supplement called 5-HTP that’s a precursor for serotonin.

Together with the L-dopa, the additional supplement has improved Alexis’s breathing point to the point that she’s now running track again. Noah’s handwriting and athletic performance have improved, and he’s better able to focus in school.

And there’s an intriguing bonus. Scientists think the gene mutation that the Beery twins inherited from their mother may be responsible for a pattern of a neuromuscular disease called fibromyalgia in her family. Fibromyalgia sometimes responds to anti-depressants called SSRIs that raise serotonin levels.

If that hypothesis pans out, it would suggest that rare genetic disorders such as DRD are just the most dramatic manifestation – in people who inherit a double dose of certain gene variants – of much more common disorders such as fibromyalgia among people who have a single copy of the mutation.

Study authors say the Beerys’ case shows how genomics will ultimately revolutionize medicine by making diagnosis more precise and pointing toward life-changing treatments. Other cases are beginning to pop up, such as a Wisconsin boy whose rare disease was diagnosed by whole-genome sequencing and subsequently treated with a bone marrow transplant. (His story appeared in a Pulitzer Prize-winning series by the Milwaukee Journal-Sentinel.)

Cost is still a big obstacle. At the time the Beery family’s genomes were sequenced, it cost around $100,000 per person. Dr. Richard Gibbs of Baylor says now, less than two years later, it would cost about half as much – less than $10,000 for the actual sequencing, plus the cost of computer processing of the results and validation.

The skeptics also point out that not all genetic insights from sequencing will lead to such cheap, simple and effective treatments as the Beery twins got.

Source: http://www.npr.org/blogs/health/2011/06/16/137204964/genome-maps-solve-medical-mystery-for-calif-twins

State changes immunization schedule

FRANKFORT Kentucky has changed its child immunization schedule to comply with national recommendations, adding a couple of childhood vaccines and recommending second “booster” immunizations for three other diseases.

“In a nutshell, the changes are to require vaccines to protect children from preventable diseases,” said Dr. William Hacker, M.D., commissioner of the Kentucky Department of Public Health. “Those diseases don’t occur as often as they once did, but they’re still serious but preventable diseases.”

Immunization requirements have been updated to better align the state’s immunization schedule with the recommendations of the Center for Disease Control and the American Academy of Pediatricians.

Hacker said many children are already taking the vaccines because physicians have  recommended them.

One of the two new vaccines is pneumococcal vaccine to prevent pneumonia, ear infections and a type of meningitis. It is recommended for children under 5 years of age. The other is meningococcal vaccine to prevent meningitis and blood-borne infections and is recommended for children entering the sixth grade.

The new guidelines also call for three “booster” vaccinations: one for chicken pox for children from kindergarten age to those entering second grade; one for tetanus, diphtheria, and pertussis for those entering sixth grade; and one for measles, mumps and rubella at 6 years old.

“We’re seeing these diseases in kids who have previously been given vaccinations,” Hacker said.

The new requirements take place July 1. Certificates for school or day care entry which are submitted after that date should meet the new vaccine requirements.

Hacker said the additional cost for the vaccines is insignificant compared to the costs of illnesses they prevent.

“These diseases can cause life-threatening infections,” Hacker said. He said local health departments and some other providers offer vaccines priced on the ability to pay.

Source: http://thetimestribune.com/local/x947029853/State-changes-immunization-schedule

Premature aging seen as issue for AIDS survivors

SAN FRANCISCO (AP) — Having survived the first and worst years of the AIDS epidemic, when he was losing three friends to the disease in a day and undergoing every primitive, toxic treatment that then existed, Peter Greene is grateful to be alive.

But a quarter-century after his own diagnosis, the former Mr. Gay Colorado, now 56, wrestles with vision impairment, bone density loss and other debilitating health problems he once assumed he wouldn’t grow old enough to see.

“I survived all the big things, but now there is a new host of things. Liver problems. Kidney disease. It’s like you are a 50-year-old in an 80-year-old body,” Greene, a San Francisco travel agent, said. “I’m just afraid that this is not, regardless of what my non-HIV positive friends say, the typical aging process.”

Even when AIDS still was almost always fatal, researchers predicted that people infected with HIV would be more prone to the cancers, neurological disorders and heart conditions that typically afflict the elderly. Thirty years after the first diagnoses, doctors are seeing these and other unanticipated signs of premature or “accelerated” aging in some long-term survivors.

Government-funded scientists are working to tease apart whether the memory loss, arthritis, renal failure and high blood pressure showing up in patients in their 40s and 50s are consequences of HIV, the drugs used to treat it or a cruel combination of both. With people over 50 expected to make up a majority of U.S. residents infected with the virus by 2015, there’s some urgency to unraveling the “complex treatment challenges” HIV poses to older Americans, according to the National Institutes of Health.

“In those with long-term HIV infection, the persistent activation of immune cells by the virus likely increases the susceptibility of these individuals to inflammation-induced diseases and diminishes their capacity to fight certain diseases,” the federal health agency’s chiefs of infectious diseases, aging and AIDS research wrote, summing up the current state of knowledge on last September’s National HIV/AIDS and Aging Awareness Day. “Coupled with the aging process, the extended exposure of these adults to both HIV and antiretroviral drugs appears to increase their risk of illness and death from cardiovascular, bone, kidney, liver and lung disease, as well as many cancers not associated directly with HIV infection.”

In San Francisco, where already more than half of the 9,734 AIDS cases are in people 50 and over, University of California, San Francisco AIDS specialists are collaborating with geriatricians, pharmacists and nutritionists to develop treatment guidelines designed to help veterans of the disease cope with getting frail a decade or two ahead of schedule and to remain independent for as long as possible.

“Wouldn’t it be helpful to be able to say, are you at high risk, low risk or moderate risk for progressing to dependency in the next five, the next 10 years, being less mobile, less able to be functional in the workplace. Are you going to be safe in your home, are you going to remember to take all those medications? How are they going to interact?” explained Dr. Malcolm John, who directs UCSF’s HIV clinic. “All those questions need to be brought into the HIV field at a younger age.”

Research so far suggests that HIV is not directly causing conditions that mimic old age, but hastens patients toward ailments to which they may have been genetically or environmentally predisposed. Plus, their immune systems are being weakened over time even when they are being successfully treated for AIDS, John said.

“That’s probably true for a lot of these things. We aren’t saying HIV’s starting the problem, but it’s added fuel on top,” he said.

Stokes, a patient of John’s who goes by only his last name, is a prime example. At 53, HIV-positive since 1985 and in substance abuse recovery for the last 11 years, he says he is happier than he ever has been. Yet the number of ailments for which he is being treated would be more commonly found in someone 30 years his senior: a condition called Ramsay Hunt syndrome that causes facial paralysis, a rare cartilage disorder for which he has undergone four ear surgeries, bone death in the hip and shoulder, deterioration of his heart muscle, osteoporosis and memory loss.

A specialist recently diagnosed a Kaposi’s sarcoma spot on Stokes’ ankle. Although the cancer is not life-threatening, the sight of young men disfigured by KS lesions was a harbinger of the early AIDS crisis, and its presence on his own body is unsettling.

At his therapy group for men with HIV, aging “comes up frequently,” he said. “I say, ‘Just think what we have come through to have a life today.’” At the same time, he acknowledges sometimes feeling self-conscious about his physical appearance and worries if “people are not attracted to me and unwilling to go the length of what it means to be with me, no matter how brilliant my mind or my zest for life.”

Loneliness, financial worries and concerns about who will care for them and where can weigh on long-term AIDS survivors in the same way as all adults living in a society that values youth, Charles Emlet, a social work professor at the University of Washington, Tacoma, said.

As they get older and sicker, many feel “doubly stigmatized,” he said. Some people who have lived with the virus for a long time have been getting by on private disability benefits that will run out when they turn 65, forcing them to move to less expensive locations or to consider turning to estranged family members. Like soldiers from a distant war, many lost partners and their closest friends to AIDS.

Such emotional side effects, combined with the physical toll of managing chronic health problems, put older AIDS patients at risk for depression. At the same time, Emlet has uncovered evidence that a majority of long-term survivors also share another trait that typically comes with advanced age: that is, the ability to draw strength from their difficult experiences.

“The older adults I’ve interviewed, many of them talk about how much it means to them to give back, to do something positive with the years they never expected to have,” he said.

Peter Greene can relate to that. At times, like the days he is so exhausted he can’t get out of bed or the pain from his multiple maladies is too intense, he asks himself “the Carrie Bradshaw question–are we really lucky to still be alive?”

As frightening and uncertain as this phase of AIDS is, he thinks he knows the answer.

“I’ve tried to make the time I have count, and really, now that I have the body of an 80-year-old, I probably have the wisdom of an 80-year-old as well, which counts for a lot,” Greene said. “Everything becomes clear at the end of your life and in some ways, thinking you’ve been dying all these years, you get moments of clarity that I don’t think everyone gets.”

Source: http://www.google.com/hostednews/ap/article/ALeqM5jSFCmOu9Y714ci26I_SOCRQvDDSQ?docId=ad4d0382cdcf430c8e325be4dd84d540

Government Lists Formaldehyde as a Known Carcinogen

After years of delays because of pressure from the chemical industry, the U.S. Department of Health and Human Services has added eight substances — including formaldehyde, which is common in household products — to its Report on Carcinogens, a science-based document that identifies chemicals and biological agents that may increase people’s risk for cancer.

Formaldehyde and a botanical known as aristolochic acids are listed as known human carcinogens. Six other substances — captafol, cobalt-tungsten carbide (in powder or hard metal form), certain inhalable glass wool fibers, o-nitrotoluene, riddelliine and styrene — are added as substances that are reasonably anticipated to be human carcinogens. With these additions, the 12th Report on Carcinogens now includes 240 listings.

“This report underscores the critical connection between our nation’s health and what’s in our environment,” says John Bucher, Ph.D., associate director of the National Toxicology Program (NTP).

The Report on Carcinogens identifies agents, substances, mixtures or exposures in two categories: known to be a human carcinogen and reasonably anticipated to be a human carcinogen. Many factors, including the amount and duration of exposure and an individual’s susceptibility to a substance, affect whether a person will develop cancer.

Formaldehyde — a colorless, flammable, strong-smelling chemical that is widely used to make resins for household items such as composite wood products, paper product coatings, plastics, synthetic fibers, and textile finishes — was first listed in the second Report on Carcinogens as a substance that was reasonably anticipated to be a human carcinogen, after laboratory studies showed it caused nasal cancer in rats. Human studies have now shown that individuals with higher measures of exposure to formaldehyde are at increased risk for certain types of rare cancers, including nasopharyngeal (the nasopharnyx is the upper part of the throat behind the nose), sinonasal, as well as a white blood cell cancer known as myeloid leukemia.

Certain inhalable glass wool fibers made the list based on experimental animal studies. Not all glass wool or man-made fibers were found to be carcinogenic. The report cites only those fibers that can enter the respiratory tract, are highly durable and remain in the lungs for long periods of time. Low-cost, general purpose glass fibers used in home and building insulation appear to be less likely to cause cancer in humans.

Styrene — a synthetic chemical used to make rubber, plastic, insulation, fiberglass, pipes, automobile parts, food containers and carpet backing — is on the list based on human cancer studies, laboratory animal studies and mechanistic scientific information. The limited evidence of cancer from studies in humans shows lymphohematopoietic cancer and genetic damage in the white blood cells, or lymphocytes, of workers exposed to styrene. People may be exposed to styrene by breathing indoor air that has styrene vapors from building materials, tobacco smoke and other products.

Intense lobbying by the chemical industry delayed the release of the Report on Carcinogens for years, Gardiner Harris reports in The New York Times. Dr. Otis Brawley, chief medical officer at the American Cancer Society, told the Times that formaldehyde is worrisome and pervasive. “It’s the smell in new houses, and it’s in cosmetics like nail polish,” he said. “All a reasonable person can do is manage their exposure and decrease it to as little as possible. It’s everywhere.”

President Obama signed a law establishing the first national standards for formaldehyde in composite wood products last year. The Formaldehyde Standards for Composite Wood Act establishes emission standards for hardwood plywood, medium density fiberboard and particleboard sold in the United States. The glue that holds together household composite wood products such as furniture, cabinets and flooring contains formaldehyde. By January 1, 2013, all products sold in the United States will have formaldehyde emissions of 0.09 parts per million or less — the most stringent standard for formaldehyde emissions in the world.

Until then new, be a conscious consumer when it comes to particleboard purchases. Use the PureBond Fabricator network to find formaldehyde-free products, and buy third-party certified furnishings and flooring. Look for the Greenguard Indoor Air Quality Certified Products seal (and check out its searchable database of low-emitting products) and the Green Seal Certified Products seal. The Pharos Project also rates and selects healthy building materials, and Scientific Certification Systems Certified Products offers Sustainable Choice and Environmentally Preferable Products programs.

Source: http://www.huffingtonpost.com/robyn-griggs-lawrence/formaldehyde-carcinogen_b_876115.html

Playing God; Is Genetic Testing The Answer To A More Pure Species?

Some parents don’t want to know the sex of their upcoming child. Others do. DNA profiling has been a hot topic amongst scientists for years and this week the topic heats up even more as a few reports published last December are now appearing on the scientific grid months later. Included in the studies is news that doctors could essentially reconstruct a baby’s genetic makeup by recovering fragments of fetal DNA from the mother’s bloodstream and determine medical conditions like Down syndrome, but also things like eye color and height and even the risk for developing depression or Alzheimer’s disease and other ailments, leaving less to fate than ever before.

Marcy Darnovsky of the Center for Genetics and Society in Berkeley, California explains:

“This really changes the experience of what it will be like to be pregnant and have a child. I keep coming up with the word, game-changer.”

Jaime King, an associate professor at the University at California Hastings College of Law in San Francisco made the following comments:

“That’s a very big burden to place on would-be parents. At the moment these things happen, it’s just you there by yourself. Some people might like that level of control, but others would be happier to leave things up to chance a little more.”

The DNA of a fetus has long been recoverable through medical procedures, with a small risk of miscarriage. But a blood test would be free of that risk, which should make many more women interested in it and doctors willing to test for a wider range of conditions, some experts say. And the results could come early enough to allow for an abortion before the pregnancy is even obvious. There lies the controversy and a barrage of moral and political fire.

Dr. Brian Skotko, a board member of the National Down Syndrome Society comments:

“If no limitations are put on, you can have a couple get a prenatal genetic test in the future saying their fetus has … a 60% chance of having breast cancer at the age of 60 and a 30% chance of being gay. The ultimate question for society is what forms of human variation are valuable?”

Should a woman be allowed to get an abortion for any reason, even a trivial one like test results about height or eye color? Some state governments have passed laws outlawing abortions on the basis of sex, she said. But it’s not clear whether those are constitutional, and a woman might simply not reveal her true reasons for wanting the abortion, King said.

Skotko points out that people use their own personal perspective in deciding what they want for their children. Some couples who are deaf from a genetic condition already use current technology to avoid having children with normal hearing.

“It’s their lens by which they view the world, and they want a child who views the world through that same lens.”

A human embryo contains 46 chromosomes organized into 23 pairs: 22 pairs of non-sex chromosomes, called autosomes, and one pair of sex chromosomes (XX in a female and XY in a male). One chromosome in each pair is inherited from the mother and one from the father.

Located along these chromosomes are approximately 25,000 genes that carry instructions for making proteins. Through the proteins they encode, your genes determine how your body develops and functions.

Source:http://www.medicalnewstoday.com/articles/228350.php

Safety Dooms Novel Staph Vaccine

A phase II/III trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, has been stopped for good following a risk-benefit analysis, according to Merck and Intercell AG.

In April, the Data Monitoring Committee recommended suspending enrollment even though a pre-specified interim analysis showed that the trial did not meet futility criteria. No explanation was given. But a decision about whether to continue the trial was put off until an analysis of the risks and benefits could be completed.

After further analysis, the Data Monitoring Committee unanimously recommended termination of the study, according to a statement from the vaccine makers.

The analysis revealed that the vaccine was unlikely to have a significant clinical benefit and may increase the risk of death and multiorgan dysfunction.

“In the additional analyses that were performed, this safety difference was not found to be statistically significant and was also determined not to warrant any action beyond routine safety follow?up,” the statement read.

The trial was designed to evaluate a single injection of V710 for preventing serious S. aureus infections in adult patients who were scheduled to undergo cardiothoracic surgery.

Merck will present the final results of the trial at an upcoming medical meeting.

Source: http://www.medpagetoday.com/InfectiousDisease/Vaccines/26921

Large Amounts of Coffee Cause Hallucinations, Study Finds

Big coffee drinkers are taking a latte break from reality, with half of them likely to hallucinate or hear things, the Herald Sun reported Wednesday.

If the break is supposed to be a stress-buster — as it often is — that makes things worse. And if a cigarette is involved, you’re playing with fire.

Research at Victorian university La Trobe found that stressed coffee lovers are three times more likely to see or hear imaginary things than everyone else.

In tests, they heard Bing Crosby singing “White Christmas” — or at least thought they did.
Professor Simon Crowe tested 92 people with varied caffeine-intake and stress levels. Subjects thought they were doing hearing tests and were initially subjected to Bing.

Then they were played three minutes of static hiss and asked to press a buzzer if they heard snippets of White Christmas in there — which there weren’t.

On average, low-caffeine subjects heard it once. But stressed coffee guzzlers buzzed three times.

“If you are stressed and have a high level of caffeine, you are more likely to notice things that aren’t there, see things that aren’t there,” Crowe said.

Source: http://www.foxnews.com/health/2011/06/08/large-amounts-coffee-cause-hallucinations-study-finds/

Parkinson’s patients have double the risk of lethal melanoma, study finds

Parkinson’s disease patients have double the risk of developing potentially lethal melanoma, government researchers reported Tuesday. Researchers have long suspected such a link, but the new study, reported in the journal Neurology, provides the strongest evidence to date.

Researchers are at a loss to explain how the link occurs biologically, but they suspect it may be a combination of environmental exposure and genetic predisposition. The association is particularly strange, experts said, because Parkinson’s patients, in general, have a below-normal risk of developing most types of cancer.

Establishing a link between Parkinson’s and melanoma is difficult because both are relatively rare diseases. About 1 million Americans have a diagnosis of Parkinson’s, and about 70,000 Americans are diagnosed with melanoma each year. The number with both diseases is therefore relatively small. To increase the chances of finding statistically significant results, Dr. Honglei Chen, a neuroscientist at the National Institute of Environmental Health Sciences in Research Triangle Park, N.C., and colleagues combined the results from 12 studies conducted between 1965 and 2010, a process known as a meta-analysis. Most of the studies had fewer than 10 patients with both conditions, but combining them yielded a number large enough for statistical significance.

Overall, the researchers found that the risk of melanoma was 2.11 times normal in Parkinson’s patients. Only some of the studies broke their results down by gender. For those studies, the team found that the risk of melanoma was 2.04 times normal for men and 1.52 times normal for women. The risk of diagnosis of melanoma was significantly higher after Parkinson’s had been diagnosed. The team found no link to non-melanoma skin cancers.

Many experts had thought that the increased risk of melanoma was produced by levo-dopa, the most common treatment for Parkinson’s disease. But recent epidemiological results, Chen noted, discount that link. Among other things, the same high risk of melanoma is associated with patients who have not received the drug.

Some studies have shown that the risks of Parkinson’s and melanoma are each increased by exposure to pesticides, and that could be a common factor in the new association, the team said. Pigmentation also may play a role: Lighter hair color is associated with an increased risk of Parkinson’s and of melanoma. The genes involved may increase concentrations of the natural hormone melanin, which exacerbates the development of melanomas.

The team concluded, however, that much more research is needed to clarify the biological basis of the links.

Source: http://www.latimes.com/health/boostershots/la-heb-parkinsons-melanoma-20110607,0,818798.story?track=rss